MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

A

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

A

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

A

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

A

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

MDT

94.77

-1.6%↓

VEEV

289

+0.99%↑

A

138.2

-0.06%↓

HQY

92.96

-1.67%↓

PHR.US

23.08

+1.81%↑

Search

Corvus Pharmaceuticals Inc

Open

6.9 0.58

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

6.9

Max

7.21

Belangrijke statistieken

By Trading Economics

Inkomsten

-23M

-8M

Winstmarge

-13,764.773

Werknemers

31

EBITDA

-360K

-10M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+96.91% upside

Dividenden

By Dow Jones

Volgende Winsten

11 nov 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

188M

520M

Vorige openingsprijs

6.32

Vorige sluitingsprijs

6.9

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Corvus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 okt 2025, 22:33 UTC

Winsten

America Movil 3Q Profit Jumps on Higher Revenue, Lower Financial Costs

14 okt 2025, 22:21 UTC

Belangrijke Marktbewegers

Dentsply Sirona Shares Rise After SEC Probe Ends

14 okt 2025, 19:27 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20 Billion

14 okt 2025, 17:56 UTC

Belangrijke Marktbewegers

Nova Minerals Surges; Will Provide Minerals Briefing to Australian Government Ahead of Trump Meeting

14 okt 2025, 23:38 UTC

Marktinformatie

Nikkei May Rise Amid Possible Bargain-Hunting -- Market Talk

14 okt 2025, 22:12 UTC

Marktinformatie
Winsten

Fletcher Building's 1H Earnings Likely Down 16% -- Market Talk

14 okt 2025, 21:40 UTC

Winsten

America Movil 3Q EBITDA MXN93.82B, Up 4.9% on Year >AMX.MX

14 okt 2025, 21:39 UTC

Winsten

America Movil 3Q Rev MXN232.92B, Up 4.2% on Year >AMX.MX

14 okt 2025, 21:38 UTC

Winsten

America Movil 3Q Net MXN22.7B Vs. Net MXN6.43B Year Ago >AMX.MX

14 okt 2025, 21:06 UTC

Winsten

These Stocks Moved the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Financial Services Roundup: Market Talk

14 okt 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 okt 2025, 20:50 UTC

Marktinformatie

Auto & Transport Roundup: Market Talk

14 okt 2025, 20:50 UTC

Marktinformatie
Winsten

Health Care Roundup: Market Talk

14 okt 2025, 20:13 UTC

Winsten

BlackRock's Assets Hit Record $13.5 Trillion After Market Rally, Dealmaking Spree -- 2nd Update

14 okt 2025, 20:01 UTC

Winsten

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 5th Update

14 okt 2025, 19:21 UTC

Marktinformatie
Winsten

Citigroup's Higher Outlook Leaves Questions -- Market Talk

14 okt 2025, 19:12 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad, Orange Offer to Buy Most Altice French Assets for About $20B

14 okt 2025, 19:08 UTC

Marktinformatie

Oil Futures Settle Lower on Trade, Oversupply Concerns -- Market Talk

14 okt 2025, 19:02 UTC

Marktinformatie

U.S. Natural Gas Falls as Weather Outlook Stays Mild -- Market Talk

14 okt 2025, 18:59 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad Group, Orange Bid for Corresponds to Total Enterprise Value of EUR17B for Altice France Assets

14 okt 2025, 18:58 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad Group, Orange Bid Excludes Stakes in Intelcia, UltraEdge, XP Fibre, Altice Technical Services

14 okt 2025, 18:58 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad Group, Orange Bid Covers Most SFR Assets

14 okt 2025, 18:56 UTC

Acquisities, Fusies, Overnames

Bouygues Telecom, Free-iliad Group, Orange Submit Joint Non-Binding Offer to Buy Large Part of Altice's Activities in France

14 okt 2025, 18:46 UTC

Winsten

These Stocks Are Moving the Most Today: JPMorgan, Wells Fargo, Goldman, AMD, Walmart, J&J, Navitas, Polaris, and More -- Barrons.com

14 okt 2025, 18:04 UTC

Winsten

Goldman Sachs Profit Surges, Fueled by Dealmaking Boom -- 4th Update

14 okt 2025, 18:01 UTC

Marktinformatie

Gold Finds Another Record as Traders Eye Further Upside -- Market Talk

14 okt 2025, 17:54 UTC

Winsten

Salesforce's Dreamforce Conference Kicks Off. CEO Benioff Touts AI Tool Agentforce. -- Barrons.com

14 okt 2025, 17:50 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 okt 2025, 17:50 UTC

Marktinformatie

Lower Dollar Provides Some Strength in Grains -- Market Talk

Peer Vergelijking

Prijswijziging

Corvus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

96.91% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 14 USD  96.91%

Hoogste 16 USD

Laagste 11 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Corvus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

3 ratings

3

Buy

0

Hold

0

Sell

Technische score

By Trading Central

3.165 / 3.5827Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Weak Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.
help-icon Live chat